Published in Proteomics Weekly, February 15th, 2010
ARQ 197 is an orally available, small molecule inhibitor of the c-Met receptor tyrosine kinase. The trials will be conducted by Daiichi Sankyo Pharma Development, a division of Daiichi Sankyo, Inc., the co-developer of ARQ 197 outside of certain...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Proteomics Weekly